Andrew Kay

Chairman

Andrew has extensive board and business experience both in Biotech and major pharmaceutical companies. Currently Chairman Nucana Plc, Chairman Blueberry Therapeutics, Consultant & Advisor to Boards and Executive teams in Biotech and Healthcare companies. Director of Amulet Consulting specialising in advisory roles with biotech.

Previously he was CEO of Algeta (top 25 biotech, oncology, acquisition market cap $2.9 Billion) with R&D/manufacturing in Europe and co-promotion in the USA. Andrew was Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics both having had successful exits. Ten years main board experience and committee experience includes Audit Committee, Compensation Committee, Corporate Governance and Regulatory Risk Committee and board sub groups for R&D, Manufacturing, financing, Licensing, clinical development. International career spans CEO, country/ business management, marketing, sales, medical/regulatory, manufacturing. Assignments include roles in the USA, UK, Italy, Switzerland and Scandinavia. Wide range of major licensing deals and product launch experience covering the major therapeutic areas and 8 blockbuster launches.

Andrew gained a BPharm Hons from Nottingham University School of Pharmacy.